U.S. FDA Approves XARELTO ® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients

XARELTO ® provides a new oral option to help prevent venous thromboembolism (VTE) and VTE-related death during hospitalization and post-hospital discharge in acutely ill medical patients at risk for VTE and not at high risk of bleedingDespite being largely preventable, VTE, or blood clots, remains a signif icant risk for millions of Americans hospitalized with an acute medical illness
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news